Aethlon Medical (NASDAQ:AEMD) Posts Earnings Results, Beats Expectations By $0.31 EPS

Aethlon Medical (NASDAQ:AEMD) announced its earnings results on Thursday. The medical equipment provider reported ($2.60) earnings per share for the quarter, topping the consensus estimate of ($2.91) by $0.31, FiscalAI reports.

Aethlon Medical Stock Performance

Shares of Aethlon Medical stock traded up $0.05 during trading on Thursday, hitting $5.58. 20,694 shares of the company’s stock were exchanged, compared to its average volume of 797,152. The stock has a market capitalization of $3.97 million, a price-to-earnings ratio of -0.16 and a beta of 1.27. The business has a 50-day simple moving average of $4.98 and a 200-day simple moving average of $7.45. Aethlon Medical has a 52-week low of $1.41 and a 52-week high of $25.66.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on AEMD. Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a report on Thursday, October 15th. HC Wainwright reaffirmed a “neutral” rating on shares of Aethlon Medical in a report on Friday, September 18th. Finally, Wall Street Zen upgraded Aethlon Medical to a “sell” rating in a research note on Saturday, October 17th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Aethlon Medical presently has a consensus rating of “Reduce” and a consensus price target of $1.50.

About Aethlon Medical

Aethlon Medical, Inc. is a biotechnology and medical-device company focused on developing extracorporeal blood filtration technologies for life-threatening diseases. The company’s lead product candidate, the Hemopurifier, is designed to selectively remove harmful substances from the bloodstream, including cancer-promoting exosomes and certain viral particles. The Hemopurifier is intended to be used with standard dialysis or blood-circulation equipment and is being investigated for potential applications in oncology and infectious disease.